Related Experiment Video
Updated: Oct 31, 2025

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons
Published on: October 10, 2025
Post-Marketing Analysis of Peripheral Neuropathy Burden with New-Generation Proteasome Inhibitors Using the FDA
Syeda A. Mina1, Ibrahim N. Muhsen2, Ethan A. Burns3
1Mayo Clinic, Department of Medicine, Rochester, USA
Abstract:
Proteasome inhibitors (PIs) are an integral component of multiple myeloma therapies. Peripheral neuropathy (PN) is a well-knownconsequence of PIs, most frequently reported with earlier generations such as bortezomib (BTZ). There is a paucity of data highlighting the risk of developing PN with the new-generation PIs carfilzomib (CFZ) and ixazomib (IZB). This study evaluated reports of PN encountered with all three PIs using the Food and Drug Administration Adverse Event (AE) Reporting System (FAERS). Signal disproportionality analysis was reported using the reporting odds ratio (ROR) with 95% confidence interval (CI). PN was reported in a total of 2.1%, 5.0%, and 10.9% of AEs with CFZ, IZB, and BTZ, respectively. The ROR (95% CI) for PN secondary to BTZ, CFZ, and IZB was 34.10 (32.76-35.49), 6.37 (5.50-7.37), and 14.97 (13.63-16.44), respectively. Compared to BTZ, CFZ and IZB have lower rates of reported PN, with RORs of 0.19 (0.16-0.22) and 0.48 (0.43-0.54), respectively.
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Peripheral Artery Disease IV: Nursing Management
Therapeutic Drug Monitoring: Affecting Factors
FDA Approved Drugs: Changes to Approved Drugs
Peripheral Artery Disease V: Postoperative Nursing Management
Therapeutic Drug Monitoring: Overview and Classification

